This study assessed the feasibility and performance of a tumor-informed circulating tumor DNA (ctDNA) assay in metastatic HR+/HER2− breast cancer patients receiving endocrine and CDK4/6 inhibitor therapy. The gene discussed is CDK4; the disease is breast cancer.